Surgical Site Infections Market Summary

• The Surgical Site Infection Treatment Market appear promising, with innovative therapies and advanced technologies on the horizon. However, there remains a crucial need for further research and the development of more personalized treatment approaches to effectively combat SSIs and address the challenges of antibiotic resistance.
• The leading Surgical Site Infection Companies such as Destiny Pharma, PolyPid, Menarini Group Pharma, Botanix Pharma, Dr. Reddy’s Laboratories Ltd., Zurex Pharma, and others.

Surgical Site Infection Market Insights & Trends

• A surgical site infection is a healthcare-associated infection that occurs at the site of a surgical procedure, caused by bacteria entering through surgical incisions. Surgical Site Infection threaten millions of patients annually and contribute to the spread of antibiotic resistance.
• According to findings, cigarette smoking has a negative impact on wound healing in orthopedic surgery with an increase in the incidence of surgical site infection of 7%.
• Avoiding razors for hair removal, maintaining normothermia, use of chlorhexidine gluconate plus alcohol–based skin preparation agents, decolonization with intranasal anti staphylococcal agents and anti staphylococcal skin antiseptics for high-risk procedures, controlling for perioperative glucose concentrations, and using negative pressure wound therapy can reduce the rate of Surgical Site Infection.
• Current Surgical Site Infection Therapies include a range of antibiotics tailored to the specific bacteria involved, such as cefazolin, vancomycin, and metronidazole. 
• Emerging therapies in the Surgical Site Infection Treatment Market Landscape focus on innovative approaches such as localized antibiotic delivery systems, like PolyPid’s D-PLEX100, and novel antimicrobial peptides, such as Destiny Pharma’s XF-73. These therapies aim to reduce infection rates and combat antibiotic resistance.

Request for Unlocking the Sample Page of the Surgical Site Infection Treatment Market

Key Factors Driving the Growth of the Surgical Site Infection Market

• Increasing Incidence of Hospital-Acquired Infections

The rising number of hospital-acquired infections worldwide is a major factor driving the growth of the surgical site infections market. Increased surgical procedures and post-operative complications continue to create demand for effective treatment and prevention solutions.

• Growing Volume of Surgical Procedures

The steady rise in the number of surgeries, including orthopedic, cardiovascular, and abdominal procedures, is contributing significantly to market expansion. A higher surgical burden increases the risk of infections, thereby boosting treatment demand.

• Advancements in Diagnostic Technologies

Innovations in diagnostic tools are improving the early detection and management of surgical site infections. Advanced microbiological testing and rapid diagnostics are supporting timely intervention and better patient outcomes.

• Rising Awareness About Infection Prevention

Healthcare providers are increasingly focusing on infection control measures and preventive care. This growing awareness is encouraging the adoption of advanced therapeutics and antimicrobial products for surgical site infection management.

• Development of Novel Therapeutics

Continuous research and development in antibiotics, antimicrobial dressings, and wound care products are enhancing treatment options. The introduction of innovative therapies is positively influencing the market growth.

• Increasing Healthcare Expenditure

Rising healthcare spending across developed and emerging countries is supporting improved surgical care infrastructure and access to advanced infection management solutions, thereby driving market expansion.

DelveInsight's “Surgical Site Infection Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of surgical site infection, historical and forecasted epidemiology as well as the Surgical Site Infection market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Surgical Site Infection Treatment Market Report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM surgical site infection market size from 2020 to 2034. The Surgical Site Infection Therapeutics Market Report also covers current surgical site infection treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Surgical Site Infection Understanding

A surgical site infection (SSI) occurs after surgery at the site of the incision, potentially affecting various depths and areas. Symptoms typically include redness, pain, swelling, drainage of cloudy or purulent fluid, and fever. SSIs generally develop within 30 days post-surgery and are classified by the CDC into three types:

• Superficial Incisional SSI Involves the skin and subcutaneous tissues directly at the incision site. 
• Deep Incisional SSI: Affects deeper tissues beneath the incision, including muscle and surrounding tissues.
• Organ or Space SSI: Occurs in areas beyond the skin and muscle, such as within organs or spaces between organs involved in the surgical procedure.
• Diagnosis involves a thorough clinical examination of symptoms, wound cultures to identify pathogens, and, if necessary, imaging studies to evaluate the extent of infection. Early detection and treatment are critical to managing SSIs effectively and preventing complications.

The Surgical Site Infection Therapeutics Market Report provides an overview of surgical site infection pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Surgical Site Infection Treatment

Treatment for Surgical Site Infections (SSIs) typically involves antibiotics tailored to the specific pathogens identified through wound cultures. The choice of antibiotics is crucial for effectively targeting the infection and reducing resistance. In some cases, if the infection does not respond to antibiotic therapy or if it involves deeper tissues or foreign materials, additional surgical intervention may be required to remove infected tissue, drain abscesses, or address complications. Prompt and appropriate management is essential to prevent the spread of infection, reduce recovery time, and minimize the risk of long-term complications.

Surgical Site Infection Epidemiology

The Surgical Site Infection epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The surgical site infection epidemiology is segmented with detailed insights into Total Incident Cases of Surgical Site Infection, Type-specific Cases of Surgical Site Infection, Organ-specific Cases of Surgical Site Infection, and Treated Cases of Surgical Site Infection

Key findings from Surgical Site Infection Epidemiological Forecast

• According to findings, surgical site infection occur in 2% to 4% of all patients undergoing inpatient surgical procedures.
• Findings show that the overall Surgical Site Infection Incidence was approximately 10% in the early 2000s, decreased to 7% by 2007, and further declined to 5% by 2020.

Surgical Site Infection Epidemiology Segmentation in the 7MM

• Total Surgical Site Infection Incident Cases
• Surgical Site Infection Type-specific Cases
• Surgical Site Infection Organ-specific Cases
• Surgical Site Infection Treated Cases

Surgical Site Infection Market Recent Breakthroughs and Developments

• In May 2026, Ondine Biomedical Inc. launched a Phase III multicenter, group-randomized, crossover study to evaluate nasal antimicrobial photodisinfection therapy (aPDT) against the standard of care for preventing surgical site infections in patients undergoing major elective, urgent, or emergency surgeries in hospital settings.

Surgical Site Infection Drug Analysis

The drug chapter segment of the Surgical Site Infection Therapeutics Market Report encloses a detailed analysis of marketed Surgical Site Infection drugs and late-stage (Phase III and Phase II) Surgical Site Infection Pipeline Drugs. It also deep dives into the Surgical Site Infection clinical trial details, recent and expected market approvals, patent details, the latest Surgical Site Infection news, and recent deals and collaborations. 

Emerging Surgical Site Infection Drugs

• D-PLEX100: PolyPid

D-PLEX is a new formulation of extended release of Doxycycline. D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable. The company is conducting a Phase III, prospective, multinational, multicenter, randomized, controlled, two-arm, double blind study to assess efficacy and safety of D-PLEX administered concomitantly with the Standard of Care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surgery incisional infection.

• XF-73 Nasal gel: Destiny Pharma

XF-73 Nasal gel, a dicationic porphyrin derivative, possesses strong bactericidal properties through a unique mechanism of action. It is a newly developed compound aimed at preventing Staphylococcal infections following surgical procedures. XF-73 Nasal gel is fast acting, requires very few applications and it has a very low propensity to develop bacterial resistance. Thus, XF-73 Nasal gel, preventing post-surgical infections, has the potential to reduce hospitalization stay, accelerate recovery and rehabilitation and improve quality of life for patients undergoing vital surgeries. In April 2024, Destiny Pharma disclosed audited results for 2023, announcing a strategic review to advance XF-73 nasal through Phase III trials. They also re-evaluated trial costs, developing a cost-effective design, and enhanced market understanding for partnerships.

Surgical Site Infection Market Outlook

The surgical site infection treatment market is anticipated to grow significantly, driven by key surgical site infection companies like PolyPid and Destiny Pharma, who are advancing their lead candidates through various clinical stages. PolyPid's D-PLEX100 and Destiny Pharma's XF-73, among other innovative therapies, aim to provide targeted and effective solutions for preventing and treating surgical site infection. The rising prevalence of surgical site infection, the increasing number of surgical procedures, and enhanced diagnostic technologies underscore the urgent need for advanced treatments. 

Surgical Site Infection Drugs Uptake

This section focuses on the uptake rate of potential surgical site infection drugs expected to be launched in the surgical site infection market during 2024–2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key surgical site infection companies evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Surgical Site Infection Clinical Trials Activities

The Surgical Site Infection Therapeutics Market Report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key Surgical Site Infection Companies involved in developing targeted therapeutics. 

Surgical Site Infection Pipeline Development Activities

The Surgical Site Infection Therapeutics Market Report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging Surgical Site Infection therapies. 

Latest KOL Views on Surgical Site Infections

To keep up with the real-world scenario in current and emerging surgical site infection market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging treatment patterns of surgical site infection. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Surgical Site Infection unmet needs.

Major Surgical Site Infection Companies

Destiny Pharma, PolyPid, Menarini Group Pharma, Botanix Pharma, Dr. Reddy’s Laboratories Ltd., Zurex Pharma, and others.

Surgical Site Infection Qualitative Analysis Report

We perform Qualitative and Surgical Site Infection Therapeutics Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. 

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. 

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Surgical Site Infection Therapeutics Market Access and Reimbursement

The Surgical Site Infection Therapeutics Market Report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Surgical Site Infection Therapeutics Market Report Scope

• The Surgical Site Infection Therapeutics Market Report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies will have an impact on the current treatment landscape.
• A detailed review of the surgical site infection therapeutics market, historical and forecasted Surgical Site Infection treatment market size, Surgical Site Infection drugs market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Surgical Site Infection Therapeutics Market Report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Surgical Site Infection Drugs Market.

Surgical Site Infection Therapeutics Market Report Insights

• Surgical Site Infection Patient Population
• Surgical Site Infection Therapeutic Approaches
• Surgical Site Infection Pipeline Drugs Analysis
• Surgical Site Infection Market Size and Trends
• Existing and Future Surgical Site Infection Drugs Market Opportunity 

Surgical Site Infection Therapeutics Market Report Key Strengths

• 11 Years Surgical Site Infection Market Forecast
• 7MM Coverage 
• Surgical Site Infection Epidemiology Segmentation
• Inclusion of country-specific treatment guidelines
• KOL’s feedback on approved and emerging therapies 
• Key Cross Competition 
• Conjoint analysis
• Surgical Site Infection Drugs Uptake
• Key Surgical Site Infection Market Forecast Assumptions

Surgical Site Infection Therapeutics Market Report Assessment

• Current Surgical Site Infection Treatment Market Practices
• Surgical Site Infection Unmet Needs
• Surgical Site Infection Pipeline Drugs Analysis Profiles
• Surgical Site Infection Drugs Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered in the Surgical Site Infection Market Report

Surgical Site Infection Treatment Market Report

• What is the growth rate of the 7MM surgical site infection treatment market?
• What was the Surgical Site Infection treatment market size, the market size by therapies, Surgical Site Infection drugs market share (%) distribution in 2020, and what would it look like in 2034? What are the contributing factors/key catalysts for this growth?
• Is there any unexplored patient setting that can open the window for growth in the future?
• What are the pricing variations among different geographies for approved and off-label therapies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends? 
• What are the current and emerging options for the treatment of surgical site infection? 
• How many Surgical Site Infection companies are developing therapies for the treatment of surgical site infections?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies? 
• Patient/physician acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? 

Reasons to Buy the Surgical Site Infection Market Report

• The Surgical Site Infection Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the surgical site infection Drugs Market.
• Insights on patient burden/disease Surgical Site Infection Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• Understand the existing Surgical Site Infection Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current surgical site infection patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming surgical site infection companies in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing surgical site infection market so that the upcoming surgical site infection companies can strengthen their development and launch strategy.

Stay updated with us for Recent Articles

• Surgical Site Infection Market: Infographics
• New DelveInsight Blogs